SLC5A2 and heart failure: Several notable areas of ongoing research include clinical trials, such as EMPEROR-Preserved and EMPEROR-Reduced, which investigate the efficacy of SGLT2 inhibitors in patients with heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), respectively [39, 40].